McAdam LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 13.9% during the third quarter, Holdings Channel.com reports. The firm owned 21,533 shares of the biopharmaceutical company’s stock after acquiring an additional 2,628 shares during the period. McAdam LLC’s holdings in Pfizer were worth $623,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth about $31,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter worth about $34,000. Institutional investors own 68.36% of the company’s stock.
Pfizer Stock Performance
Shares of NYSE PFE opened at $28.65 on Friday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The stock’s 50 day moving average price is $29.07 and its 200-day moving average price is $28.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.86%. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. UBS Group raised their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $33.91.
Check Out Our Latest Research Report on PFE
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
- Five stocks we like better than Pfizer
- How to Invest in Blue Chip Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Dividend Capture Strategy: What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Stock Sentiment Analysis: How it Works
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.